Schmitz, Gerd (2006) Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 8 (6). pp. 547-554. ISSN 1464-8431,
Full text not available from this repository. (Request a copy)Abstract
OncoGenex Technologies Inc in collaboration with Isis Pharmaceuticals Inc is developing OGX-011, an intravenously administered clusterin-inhibiting antisense oligonucleotide, to potentially sensitize solid tumors that are resistant to conventional cancer therapeutics. Phase II clinical trials of OGX-011 in combination with chemotherapeutic drugs are underway in NSCLC, prostate and breast cancer.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PROSTATE-CANCER; IN-VITRO; GENE; CELLS; VIVO; PROGRESSION; CHAPERONE; THERAPY; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Klinische Chemie und Laboratoriumsmedizin |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 15 Jan 2021 13:17 |
| Last Modified: | 15 Jan 2021 13:17 |
| URI: | https://pred.uni-regensburg.de/id/eprint/33680 |
Actions (login required)
 |
View Item |
